Avadel Pharmaceuticals plc (AVDL)
Automate Your Wheel Strategy on AVDL
With Tiblio's Option Bot, you can configure your own wheel strategy including AVDL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AVDL
- Rev/Share 2.5593
- Book/Share 1.0115
- PB 21.3337
- Debt/Equity 0.3805
- CurrentRatio 2.7562
- ROIC 0.0028
- MktCap 2110903808.0
- FreeCF/Share 0.3646
- PFCF 59.6199
- PE -7537.7853
- Debt/Assets 0.1874
- DivYield 0
- ROE -0.0033
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | AVDL | H.C. Wainwright | Buy | Neutral | -- | $20 | Oct. 23, 2025 |
| Initiation | AVDL | Wells Fargo | -- | Equal Weight | -- | $16 | Sept. 3, 2025 |
| Resumed | AVDL | H.C. Wainwright | -- | Buy | -- | $22 | July 18, 2025 |
| Initiation | AVDL | Deutsche Bank | -- | Buy | -- | $12 | Feb. 11, 2025 |
News
Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a CNS Drugs supplement titled “A New Dawn in the Management of Narcolepsy”.
Read More
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets.
Read More
About Avadel Pharmaceuticals plc (AVDL)
- IPO Date 1996-06-07
- Website https://www.avadel.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Gregory J. Divis Jr.
- Employees 188